

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions,
and listings, of claims in the application:

LISTING OF CLAIMS:

1-25. (cancelled)

26. (currently amended) A hybrid promoter comprising :

a) a peroxisome proliferator activated receptor response
element (PPAR response element) comprising at least
one PPAR-binding site; and

b) a heterologous sequence from a promoter of a IIA-1
nonpancreatic secreted phospholipase A2 (PLA2s) gene
or a ~~functional part~~ sequence of a PLA2s gene
comprising at least residues 51 to 61, 23 to 32, 148
to 155, 5 to 170 or 51 to 170 of SEQ ID NO.5.

27. (currently amended) The hybrid promoter according to
Claim 26, wherein the PPAR response element has repetition of
the same binding site or a combination of different binding
sites.

28. (currently amended) The hybrid promoter according to
Claim 27, wherein the PPAR response element comprises one or

RECEIVED
DEC 16 2003
TECH CENTER 1600/2900

more sites having the nucleic acid sequence of SEQ ID NO.1 or a functional variant of SEQ ID NO.1.

29. (currently amended) The hybrid promoter according to Claim 26, wherein the PPAR response element comprises the nucleic acid sequence of ~~SEQ ID NOS~~ SEQ ID NOS. 1, 2, 3 or 4 or a functional variant of ~~SEQ ID NOS~~ SEQ ID NOS. 1, 2, 3 or 4.

30. (cancelled)

31. (currently amended) The hybrid promoter according to Claim 26, wherein said functional part of the PLA2s promoter is induced by interleukin-1 β .

32-34. (cancelled)

35. (currently amended) The hybrid promoter according to Claim 26, wherein said PPAR response element is positioned 5' upstream of said ~~functional part~~ sequence of said PLA2s gene comprising at least residues 51 to 61, 23 to 32, 148 to 155, 5 to 170 or 51 to 170 of SEQ ID NO.5.

36. (currently amended) The hybrid promoter according to Claim 26, comprising ~~further comprises~~ a nucleic acid sequence ~~gene~~ that confers tissue specificity.

37. (currently amended) The hybrid promoter according to Claim 36, wherein said sequence ~~gene~~ confers specificity for ~~the~~ chondrocytic cells.

38. (currently amended) The hybrid promoter according to Claim 36, wherein said sequence ~~gene~~ comprises SEQ ID NO:7, a ~~functional part of SEQ ID NO:7 or a variant of SEQ ID NO:7.~~

39. (currently amended) A An isolated nucleic acid ~~sequence~~ comprising the nucleic acid sequence selected from the group consisting of SEQ ID NOS SEQ ID NOS. 1, 2, 3, 4 ~~or~~ and 5 ~~or~~ a ~~functional variant of SEQ ID NOS 1, 2, 3, 4 or 5.~~

40. (currently amended) The isolated nucleic acid according to Claim 39, further comprising a nucleic acid sequence encoding an anti-inflammatory product.

41. (currently amended) A vector comprising a nucleic acid sequence comprising ~~encoding~~ said hybrid promoter according to Claim 26.

42. (currently amended) A vector comprising a nucleic acid sequence comprising encoding said hybrid promoter nucleic acid according to Claim 35.

43. (previously presented) The vector according to claim 41, wherein said vector is a plasmid.

44. (previously presented) The vector according to claim 42, wherein said vector is a plasmid.

45. (currently amended) A composition comprising (i) a the isolated nucleic acid according to claim 39 and (ii) a PPAR activator.

46. (currently amended) A composition comprising (i) a the vector according to claim 41 and (ii) a PPAR activator.

47. (currently amended) A composition comprising (i) a the vector according to claim 42 and (ii) a PPAR activator.

48. (currently amended) A nucleic acid comprising a sequence selected from the group consisting ~~class~~ of SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4.

49. (previously presented) A nucleic acid comprising the sequence of SEQ ID NO:6.

50. (currently amended) A An isolated cell comprising a the hybrid promoter according to claim 26.

51. (currently amended) A An isolated cell comprising a the hybrid promoter according to claim 41.

52. (currently amended) A An isolated cell comprising a the hybrid promoter according to claim 42.